Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 166
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Aromatase Inhibitor Clinical Trial
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Biomarker/Laboratory analysis, Treatment
Active
40 to 70
NIGMS
0412-14
UO1-GM61373-06, NCT00228956
2.
Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Biomarker/Laboratory analysis, Treatment
Active
18 to 45
Other
0501-37
NCT00352872
3.
Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-Menopausal Women With Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Active
50 and over
Pharmaceutical / Industry
CFEM345DUS59
NCT00688909
4.
Using the Conture® Multi-Lumen Balloon to Deliver Accelerated Partial Breast Brachytherapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Active
50 and over
Other
SENORX-S07-002
NCT00699101
5.
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Biomarker/Laboratory analysis, Treatment
Active
18 to 85
Other
20050113
NCT00243685
Last Modified:
1/4/2007
 
First Published:
10/24/2006
6.
Phase II/III Study of Neoadjuvant Therapy Comprising Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) (Abraxane®) in Women With Previously Untreated, Unresected, Stage II-IIIB Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
18 and over
Other
WHC-MRI-GU-2006-097
NCT00397761
7.
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
65 and over
Other
0120070323
NCT00698971
Last Modified:
10/9/2008
 
First Published:
1/1/1998
8.
Phase III Randomized Study of Letrozole Versus Placebo in Postmenopausal Women With Primary Breast Cancer Who Have Completed at Least Five Years of Adjuvant Aromatase Inhibitor
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
Postmenopausal
NCI, Pharmaceutical / Industry
CAN-NCIC-MA17
CALGB-49805, E-JMA17, EORTC-10983, IBCSG-BIG97-01, NCCTG-JMA17, SWOG-JMA17, JRF-Vor-Int-10, NCCTG-CAN-MA17, SWOG-CAN-MA17, NCT00003140, JMA17, MA17
Last Modified:
10/9/2008
 
First Published:
7/1/2002
9.
Phase III Randomized Study of Two Different Schedules of Adjuvant Cyclophosphamide and Doxorubicin Versus Paclitaxel in Women With Operable Breast Cancer and 0-3 Positive Axillary Lymph Nodes
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
NCI
CALGB-40101
CALGB-40101, NCT00041119
Last Modified:
10/9/2008
 
First Published:
7/26/2003
10.
Phase III Randomized Study of Ovarian Function Suppression in Combination With Tamoxifen Versus Ovarian Function Suppression in Combination With Exemestane Versus Tamoxifen Alone in Premenopausal Women With Endocrine-Responsive Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
Premenopausal
NCI
IBCSG-2402
BIG-2-02, CALGB-IBCSG-2402, CAN-NCIC-IBCSG-2402, NCCTG-IBCSG-2402, NSABP-IBCSG-2402, SWOG-IBCSG-2402, NABCI-IBCSG-2402, UCLA-0403024-01, EU-20334, IBCSG-24-02, NCT00066690, EUDRACT-2004-000166-13
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute